Site Search
Search Results
Cancer Biomarker Testing
... cancer therapies that have improved patient outcomes and quality of life within populations of cancer patients with very specific biomarkers. Testing patients for cancer biomarkers is integral to identify those who may benefit from targeted therapy. Despite the importance of such testing, ... advancements in targeted cancer therapies and data from ACS CAN Survivor Views surveys of cancer patients and survivors assessing barriers to biomarker testing. Cancer Biomarker Testing ...
Improving Access to Biomarker Testing
... led to targeted cancer therapies that can improve patient survival and quality life. Treatment with targeted therapy often requires diagnostic testing to analyze biological samples taken from patients to identify and evaluate cancer biomarkers. Testing patients for specific biomarkers is integral to precision medicine in cancer care, but despite evidence pointing to the clinical benefits associated with biomarker testing, routine clinical use does not always follow, and testing rates lag behind clinical guideline recommendations. As highlighted in a recent ACS CAN survey of cancer patients and survivors, only one-third of respondents reported having biomarker testing. Of those who reported not receiving biomarker testing, more than a quarter said it was because insurance would not cover it or ...
Impact of Comprehensive Biomarker Testing
Illustrative stories about the impact of timely testing and the importance of insurance coverage for comprehensive biomarker testing – not only to improve patient outcomes and quality of life but also to avoid ineffective treatments and disease progression. Impact of Comprehensive Biomarker Testing ...
Understanding Provider Utilization of Cancer Biomarker Testing
Biomarker testing is an important step to accessing precision medicine, including targeted therapies that can lead to improved survivorship and better quality of life for cancer patients. However, not all communities are benefitting from the latest advancements in biomarker testing and precision medicine. ACS CAN is working to dismantle barriers that prevent patients from benefiting from biomarker testing and precision ...
Understanding Provider Utilization of Cancer Biomarker Testing
Biomarker testing is an important step to accessing precision medicine, including targeted therapies that can lead to improved survivorship and better quality of life for cancer patients. However, not all communities are benefitting from the latest advancements in biomarker testing and precision medicine. ACS CAN is working to dismantle barriers that prevent patients from benefiting from biomarker testing and precision ...
Health Equity in Biomarker Testing and Targeted Therapy
Despite evidence demonstrating the effectiveness of biomarker testing and targeted therapy, currently not all individuals benefit equitably from these advances. There are notable racial/ethnic, and ... socioeconomic disparities in access and utilization of these advancements in care. These disparities in access and use of guideline-indicated biomarker testing and targeted therapy can potentially widen existing disparities in cancer survival. Health Equity in Biomarker Testing and ...
Payer Coverage Policies of Tumor Biomarker and Pharmacogenomic Testing
Biomarker testing is key to unlocking precision medicine and improving cancer outcomes, however not all individuals are benefiting. In a survey of over 300 oncology providers, 66% reported that insurance coverage for biomarker testing is a moderate or significant barrier to appropriate testing for their patients. Additionally, 91% indicated that they consult clinical ...
The Landscape of Biomarker Testing Coverage in the U.S.
Biomarker testing is becoming increasingly important for cancer care because it connects the right patient, to the right treatment, at the right time, however insurance coverage of testing varies widely. This study, that examines administrative claims data to understand the premium impact of expanding biomarker testing coverage in four markets: commercial self-insured large group, small group, individual, and Medicaid, found a small potential ...
Pharmacogenomic (PGx) Testing: Tests Guide Appropriate Drug Selection and Dosing
Pharmacogenomic (PGx) testing (also known as pharmacogenomic biomarker testing) is a component of precision medicine that involves examining a patient’s inherited genes to detect variations that may impact the way a ... treatment given to patients with the same disease can produce different responses based on each person's inherited genes. Pharmacogenomic (PGx) Testing: Tests Guide Appropriate Drug Selection and Dosing ...
Cancer Patients and Survivors Overwhelmingly Agree Biomarker Testing Improved Their Treatment
... to support ACS CAN’s advocacy work at all levels of government. Fielded September 12-25, 2023, our latest survey explores experiences with biomarker testing. The web-based survey was conducted among 1,222n cancer patients and survivors nationwide who have been diagnosed with or treated for cancer in the last seven years. Summary of Findings Higher Income and Education Groups are Most Likely to Report Having and Asking for Biomarker Testing About half (49%) of those surveyed have had biomarker testing for their cancer, while 29% say they have not and 22% are unsure. ...